Grisefuline

Grisefuline is an oral antifungal medication whose active ingredient is griseofulvin. It is supplied without a specified strength or dosage form, and is marketed in the European Union as a prescription (Rx) product. Griseofulvin belongs to the antifungal drug class and works by disrupting fungal cell division. The product is used primarily for treating dermatophyte infections of the skin, hair, and nails and associated conditions worldwide generally.

Grisefuline is indicated for several common dermatophyte infections that affect the skin, scalp, feet, and nails. These infections are caused by fungi that invade keratinized tissues, and griseofulvin helps to eradicate the organisms over several weeks of therapy.

- Tinea corporis (ringworm of the body) - Tinea capitis (scalp ringworm) - Tinea pedis (athlete’s foot) - Onychomycosis (fungal nail infection) - Other dermatophyte infections such as tinea cruris (jock itch) - Occasionally used for extensive cutaneous dermatophytosis

Side effects of Grisefuline vary in frequency and severity; some are mild and transient, while others may require medical attention.

Common: - Headache, often mild and transient - Nausea or vomiting, usually occurring early in treatment - Abdominal discomfort or dyspepsia - Rash or mild skin itching - Increased sensitivity to sunlight (photosensitivity)

Serious: - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity, indicated by elevated liver enzymes or jaundice - Blood disorders including leukopenia, thrombocytopenia, or anemia - Peripheral neuropathy presenting as tingling or numbness - Acute allergic reactions, including angioedema or anaphylaxis

Before initiating Grisefuline therapy, healthcare providers should evaluate several precautionary factors to minimize risks and ensure appropriate use.

- Assess liver function because griseofulvin is metabolized hepatically. - Review patient’s medical history for hematologic disorders. - Caution in patients with known photosensitivity or those taking other photosensitizing agents. - Use during pregnancy only if potential benefit justifies risk, as safety data are limited. - Monitor for drug interactions, especially with oral contraceptives and anticoagulants. - Advise patients to avoid excessive sun exposure and use protective clothing. - Consider baseline complete blood count for long‑term therapy.

Grisefuline can affect the metabolism of other medicines; certain combinations should be avoided, while others require careful monitoring.

Avoid: - Oral contraceptives (reduced efficacy) - Phenobarbital, carbamazepine, phenytoin (induction of metabolism, decreasing griseofulvin levels)

Use with caution: - Warfarin (potential alteration of anticoagulant effect) - Antifungal agents such as itraconazole (possible additive toxicity) - Cyclosporine (increased risk of nephrotoxicity) - Vitamin A supplements (risk of hypervitaminosis A) - Immunosuppressants (monitor for altered response)